Papulopustular Rosacea
Conditions
Interventions
Minocycline group:Oral Minocycline Hydrochloride Capsules
AWL-PDT group:AWL-PDT
DL-PDT group:DL-PDT
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years and older; 2. Patients diagnosed with papulopustular rosacea according to the 2017 Rosacea Consensus (ROSCO), with a disease duration of more than 6 months; 3. Patients who comply with the study or follow-up procedures and cooperate in observing adverse events and treatment efficacy; 4. Patients who have signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with a history of allergy to aminolevulinic acid hydrochloride (ALA) or similar compounds, a history of photosensitivity, or an allergy to minocycline hydrochloride; 2. Participation in any clinical study involving investigational drugs within 1 month prior to enrollment; 3. Use of topical antibiotics, retinoids, corticosteroids, benzoyl peroxide, or other medications affecting rosacea symptoms within 1 month prior to treatment; 4. Severe diseases of major organs such as heart, liver, lungs, kidneys, or hematopoietic system disorders, or other conditions deemed unsuitable for clinical trial participation by the investigators; 5. Patients with malignant tumors, general debilitation, or immunodeficiency; 6. Patients with combined atopic dermatitis, steroid-dependent dermatitis, or other facial skin-related diseases; 7. History of sunburn in the past month; 8. Drug, tobacco, or alcohol addiction; 9. Patients with a history of epilepsy, family history of epilepsy, tic disorders, or other mental illnesses may be unable to cooperate; 10. Pregnant or breastfeeding women; 11. Received phototherapy or laser treatments in the past three months; 12. Patients with other types of rosacea, such as erythematotelangiectatic type or rhinophyma type; 13. Patients who cannot or are unwilling to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Papules and Pustules; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Clinician’s Erythema Assessment, CEA;Rosacea-Specific Quality of Life Scale Score;Investigator’s global assessment Score, IGA; | — |
Countries
China
Contacts
Public ContactJian Li
The First Affiliated Hospital of Army Medical University
Outcome results
None listed